Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination antibiotic therapy consisting of gentamicin (an aminoglycoside), meropenem (a carbapenem), and vancomycin (a glycopeptide). The combination has shown enhanced killing action against various bacteria, including Pseudomonas aeruginosa and Staphylococcus aureus. Studies have demonstrated that the addition of gentamicin to meropenem enhances bactericidal activity against P. aeruginosa, while the addition of vancomycin to meropenem improves activity against staphylococci, including methicillin-resistant strains. This combination has been used in cases of severe infections, including sepsis, endocarditis, and complicated urinary tract infections, particularly when dealing with resistant organisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + meropenem + vancomycin.